Table 3.
Clinical data of IPD patients grouped according to SN size in TCS
| Data | Whole IPD group* (n = 183) | IPD patients SN <= 0.2 cm2* (n = 9) | IPD patients SN>0.2 cm2* (n = 174) | p-value (Mann-Whitney-Test) |
|---|---|---|---|---|
| Age, y | 66 (62;71) | 69 (67;75) | 66 (62;71) | 0.18 |
| Age at disease onset, y | 61 (54;66) | 67 (59;74) | 60 (54;66) | 0.13 |
| Disease duration, months | 78 (48;120) | 60 (36;96) | 81 (48;120) | 0.23 |
| Duration since L-Dopa start, y | 5 (3; 8) | 3 (1,5;2,2) | 5 (3;8) | 0.37 |
| L-Dopa equivalent dose, mg | 560 (310;679) | 519 (306;628) | 558 (310;679) | 0.83 |
| Hoehn&Yahr score | 2.5 (2.5;3) | 2.5 (2.5;2.5) | 2.5 (2.5;3) | 0.88 |
| UPDRS III score | 26 (17;34) | 27 (20;31) | 25 (17;34) | 0.28 |
| Pegboard test score | 16 (12;20) | 13 (13;14) | 16 (12;20) | 0.03 |
| Webster gait test | 13 (10;15) | 13 (13;18) | 12 (11;15) | 0.37 |
*Data are given as median with lower and upper quartile (25th and 75th percentile respectively). y (years)